[HTML][HTML] It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. Menu
MM Rashida, H Leea, BH Junga - pazopanibinhibitor.com
ABSTRACT PP242 is a second generation novel selective ATP-competitive inhibitor of
mTOR that displayed promising anti-cancer activity over several cancer types by inhibiting …
mTOR that displayed promising anti-cancer activity over several cancer types by inhibiting …
Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass …
PP242 is a second generation novel selective ATP-competitive inhibitor of mTOR that
displayed promising anti-cancer activity over several cancer types by inhibiting both the …
displayed promising anti-cancer activity over several cancer types by inhibiting both the …
Abstract 393A: Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620
F Beaufils, D Rageot, A Melone, A Sele, M Lang… - Cancer Research, 2016 - AACR
Introduction: The mammalian target of rapamycin (mTOR) signaling pathway is an
integrating factor in cell physiology that influences many processes like growth, metabolism …
integrating factor in cell physiology that influences many processes like growth, metabolism …
Abstract B146: XL388: a novel, selective, orally bioavailable mTORC1 and mTORC2 inhibitor that demonstrates pharmacodynamic and antitumor activity in multiple …
N Miller - Molecular Cancer Therapeutics, 2009 - AACR
Background: The mTOR kinase exists in at least two distinct kinase complexes, mTORC1
and mTORC2 which collectively regulate cell growth, proliferation, survival, autophagy, and …
and mTORC2 which collectively regulate cell growth, proliferation, survival, autophagy, and …
Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR
S Chen, J Liu, X Wang, C Liang, J Ding… - Biochemical …, 2012 - Elsevier
The mammalian target of rapamycin (mTOR), is deregulated in about 50% of human
malignancies and exists in two complexes: mTORC1 and mTORC2. Rapalogs partially …
malignancies and exists in two complexes: mTORC1 and mTORC2. Rapalogs partially …
Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor
F Beaufils, D Rageot, A Melone, M Lang, J Mestan… - Cancer Research, 2016 - AACR
Mammalian target of rapamycin (mTOR) signaling pathway plays a fundamental role in cell
proliferation, differentiation, growth and survival.[1] As a consequence, various tumors and …
proliferation, differentiation, growth and survival.[1] As a consequence, various tumors and …
Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
Abstract The phosphoinositide 3-kinase (PI3-K)/Akt and mTOR signaling pathway plays a
critical role in cell survival and proliferation and is often aberrantly activated in many types of …
critical role in cell survival and proliferation and is often aberrantly activated in many types of …
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
DS Mortensen, KE Fultz, S Xu, W Xu, G Packard… - Molecular cancer …, 2015 - AACR
Abstract mTOR is a serine/threonine kinase that regulates cell growth, metabolism,
proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) …
proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) …
OSI-027, a selective dual mTORC1/TORC2 kinase inhibitor displays broad spectrum anti-tumor activity in preclinical models of human cancer
PC Gokhale, SV Bhagwat, AP Crew, A Cooke, C Mantis… - Cancer Research, 2010 - AACR
The mammalian target of rapamycin (mTOR) protein kinase plays a central role in regulating
cell proliferation and cell survival. The PI3K/AKT signaling pathway that activates mTOR is …
cell proliferation and cell survival. The PI3K/AKT signaling pathway that activates mTOR is …
[PDF][PDF] Current status of mTOR inhibitors as novel therapeutic agents
R Gill, A Tripathy, KL Bairy - J. Glob. Pharma Technol, 2009 - academia.edu
Mammalian target of rapamycin (mTOR) is a PI3K (phosphatidylinositol-3-kinase)-related
kinase, via two distinct forms–mTOR complex 1 (mTORC1) and mTORC2 coordinates …
kinase, via two distinct forms–mTOR complex 1 (mTORC1) and mTORC2 coordinates …